Graphite Bio, Inc. (NASDAQ:GRPH) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics' First Quarter 2026 Financial Results Conference Call.
Graphite Corp (GRPH)
This company is not actively trading or the ticker does belong to another company in our database now.
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.05 | 20,000,000 | $1,074,000.00 | 30,000,000 | 2014-10-08 | Filing | |
| $0.05 | 10,000,000 | $537,000.00 | 30,000,000 | 2014-08-09 | Filing | |
| $0.05 | 20,000,000 | $1,074,000.00 | 30,000,000 | 2014-10-08 | Filing | |
| $0.05 | 10,000,000 | $537,000.00 | 30,000,000 | 2014-08-09 | Filing | |
| $1,074,000.00 | 20,000,000 | $21,480,000,000,000.00 | 30,000,000 | 2014-10-08 | Filing |
News See All
Graphite Bio, Inc. (NASDAQ:GRPH) Q4 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year-end 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
11 Stocks that Paid Special Dividends in 2024
In this article, we discuss 11 stocks that paid special dividends in 2024.
12 Gene Editing Stocks With the Best Long-Term Potential
In this article, we will take a look at the 12 gene editing stocks with the best long-term potential.
11 Most Promising Gene Editing Stocks According to Analysts
In this article, we will take a look at the 11 most promising gene editing stocks according to analysts.
5 Best Gene Editing Stocks To Buy
Graphite Bio, Inc. (NASDAQ:GRPH) is a clinical-stage gene editing company based in San Francisco, California. It develops therapies for life-threatening diseases in the United States.
Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs' Samsara BioCapital
In this article, we discuss the top 5 stock picks of Srini Akkaraju and Michael Dybbs' Samsara BioCapital.
5 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs' Samsara BioCapital
In this article, we will discuss 5 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs' Samsara BioCapital.
Hedge Fund Resource Center